Literature DB >> 7006846

MItomycin C, methyl-CCNU and 5-fluorouracil in the treatment of metastatic colorectal carcinoma.

P D Bonomi, G Chandra, A H Rossof, D Klaassen.   

Abstract

The combination of mitomycin C, methyl-CCNU and 5-fluorouracil produced no objective tumor regressions in 25 evaluable patients with metastatic colorectal carcinoma. Patients who achieved stable disease survived significantly longer than patients who had progressive disease. This difference appeared to be more probably related to pre-treatment characteristics of the patients than caused by treatment. Serial CEA determinations revealed a parallel relationship with tumor behavior in 17 of 19 patients.

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 7006846     DOI： 10.1007/bf00578560

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN： 0344-5704            Impact factor:   3.333


  9 in total

1.  Clinical management of advanced gastrointestinal cancer.

Authors:  C G Moertel
Journal:  Cancer       Date:  1975-08       Impact factor: 6.860

2.  Combination of constant-infusion 5-fluorouracil, methyl-CCNU, mitomycin C, and vincristine in advanced colorectal carcinoma.

Authors:  F A Greco; R L Richardson; S F Shulman; R K Oldham
Journal:  Cancer Treat Rep       Date:  1978-09

3.  Phase III comparison of the treatment of advanced gastrointestinal cancer with bolus weekly 5-FU vs. methyl-CCNU plus bolus weekly 5-FU. A Southwest Oncology Group study.

Authors:  L H Baker; R W Talley; R Matter; D E Lehane; B W Ruffner; S E Jones; F S Morrison; R L Stephens; E A Gehan; V K Vaitkevicius
Journal:  Cancer       Date:  1976-07       Impact factor: 6.860

4.  5-Fluorouracil (5-FU), methyl-CCNU, and vincristine in the treatment of advanced colorectal cancer: phase II study utilizing weekly 5-FU.

Authors:  J S Macdonald; D F Kisner; T Smythe; P V Woolley; L Smith; P S Schein
Journal:  Cancer Treat Rep       Date:  1976-11

5.  Therapy of advanced colorectal cancer with a combination of 5-fluorouracil, methyl-1,3-cis(2-chlorethyl)-1-nitrosourea, and vincristine.

Authors:  C G Moertel; A J Schutt; R G Hahn; R J Reitemeier
Journal:  J Natl Cancer Inst       Date:  1975-01       Impact factor: 13.506

6.  The value of serial carcinoembryonic antigen (CEA) in predicting response rate and survival of patients with gastrointestinal cancer treated with chemotherapy.

Authors:  M Al-Sarraf; L Baker; R W Talley; K Kithier; V K Vaitkevicius
Journal:  Cancer       Date:  1979-10       Impact factor: 6.860

7.  Fluorouracil, methyl-CCNU and vincristine in cancer of the colon.

Authors:  G Falkson; H C Falkson
Journal:  Cancer       Date:  1976-10       Impact factor: 6.860

8.  Serial plasma carcinoembryonic antigen measurements in the management of metastatic colorectal carcinoma.

Authors:  A Shani; M J O'Connell; C G Moertel; A J Schutt; A Silvers; V L Go
Journal:  Ann Intern Med       Date:  1978-05       Impact factor: 25.391

9.  Lack of effectiveness of combined 5- fluorouracil and methyl-CCNU therapy in advanced colorectal cancer.

Authors:  J J Lokich; A T Skarin; R J Mayer; E Frei
Journal:  Cancer       Date:  1977-12       Impact factor: 6.860
  9 in total
  2 in total

1.  Palliative and adjunctive measures in rectal cancer.

Authors:  A Fritsch; W Seidl; C Walzel; K Moser; R Schiessel
Journal:  World J Surg       Date:  1982-09       Impact factor: 3.352

2.  Vindesine: phase II evaluation in colon cancer and description of its platelet stimulating activity.

Authors:  R Pazdur; A H Rossof; G Chandra; P D Bonomi; R E Slayton; J Wolter
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.